The dawn of precision medicine in HIV: state of the art of pharmacotherapy

被引:14
作者
Mu, Ying [1 ]
Kodidela, Sunitha [2 ]
Wang, Yujie [2 ]
Kumar, Santosh [2 ]
Cory, Theodore J. [1 ]
机构
[1] Univ Tennessee, Ctr Hlth Sci, Coll Pharm, Dept Clin Pharm & Translat Sci, Memphis, TN 38163 USA
[2] Univ Tennessee, Ctr Hlth Sci, Coll Pharm, Dept Pharmaceut Sci, Memphis, TN 38163 USA
基金
美国国家卫生研究院;
关键词
Antiretroviral therapy; pharmacokinetics; pharmacodynamics; pharmacogenetic; precision medicine; therapeutic monitoring; POPULATION PHARMACOKINETIC ANALYSIS; EFAVIRENZ PLASMA-CONCENTRATIONS; CHRONIC KIDNEY-DISEASE; OPEN-LABEL TRIAL; ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE; INFECTED PATIENTS; PROTEASE INHIBITOR; DRUG-RESISTANCE; ATAZANAVIR PHARMACOKINETICS;
D O I
10.1080/14656566.2018.1515916
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Combination antiretroviral therapy (ART) reduces viral load to under the limit of detection, successfully decreasing HIV-related morbidity and mortality. Due to viral mutations, complex drug combinations and different patient response, there is an increasing demand for individualized treatment options for patients.Areas covered: This review first summarizes the pharmacokinetic and pharmacodynamic profile of clinical first-line drugs, which serves as guidance for antiretroviral precision medicine. Factors which have influential effects on drug efficacy and thus precision medicine are discussed: patients' pharmacogenetic information, virus mutations, comorbidities, and immune recovery. Furthermore, strategies to improve the application of precision medicine are discussed.Expert opinion: Precision medicine for ART requires comprehensive information on the drug, virus, and clinical data from the patients. The clinically available genetic tests are a good starting point. To better apply precision medicine, deeper knowledge of drug concentrations, HIV reservoirs, and efficacy associated genes, such as polymorphisms of drug transporters and metabolizing enzymes, are required. With advanced computer-based prediction systems which integrate more comprehensive information on pharmacokinetics, pharmacodynamics, pharmacogenomics, and the clinically relevant information of the patients, precision medicine will lead to better treatment choices and improved disease outcomes.
引用
收藏
页码:1581 / 1595
页数:15
相关论文
共 175 条
[1]   Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers [J].
Abdelhady, Ahmed M. ;
Shugg, Tyler ;
Thong, Nancy ;
Lu, Jessica Bo Li ;
Kreutz, Yvonne ;
Jaynes, Heather A. ;
Robarge, Jason D. ;
Tisdale, James E. ;
Desta, Zeruesenay ;
Overholser, Brian R. .
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2016, 27 (10) :1206-1213
[2]  
Abhyanker R, VIRCONET TRADEMARK I
[3]  
Ahuja SK, 2008, NAT MED, V14, P413, DOI 10.1038/nm1741
[4]  
Altmann A, KEEPING MODELS PREDI
[5]   Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: A pilot study [J].
Anderson, Peter L. ;
Lamba, Jatinder ;
Aquilante, Christina L. ;
Schuetz, Erin ;
Fletcher, Courtney V. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 42 (04) :441-449
[6]   Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors [J].
Anderson, Peter L. ;
Aquilante, Christina L. ;
Gardner, Edward M. ;
Predhomme, Julie ;
McDaneld, Patrick ;
Bushman, Lane R. ;
Zheng, Jia-Hua ;
Ray, Michelle ;
MaWhinney, Samantha .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (05) :1071-1079
[7]  
[Anonymous], PLOS ONE
[8]  
[Anonymous], 2017, BIOMED RES INT, DOI DOI 10.1155/2017/
[9]  
[Anonymous], 2011, GUIDELINES USE ANTIR
[10]   Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals [J].
Aouri, Manel ;
Barcelo, Catalina ;
Guidi, Monia ;
Rotger, Margalida ;
Cavassini, Matthias ;
Hizrel, Cedric ;
Buclin, Thierry ;
Decosterd, Laurent A. ;
Csajka, Chantal .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (01)